Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.36 is in line with its 5-year average of -0.39, around the middle of its 5-year range (-0.61–-0.15).
38.98% above its 12-month average of -0.59.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.05.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.36
EARNINGS PER SHARE (EPS) AVG TTM
-0.59
EARNINGS PER SHARE (EPS) AVG 3Y
-0.49
EARNINGS PER SHARE (EPS) AVG 5Y
-0.39
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+38.98%
CURRENT VS 3Y AVG
+26.15%
CURRENT VS 5Y AVG
+7.69%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
OmniAb, Inc.
Market Cap
$630.63M
Earnings Per Share (EPS)
-0.36
TTM Avg
-0.59
3Y Avg
-0.49
5Y Avg
-0.39
Market Cap
$632.16M
Earnings Per Share (EPS)
-1.10
TTM Avg
-1.50
3Y Avg
-1.66
5Y Avg
-1.44
Market Cap
$634.30M
Earnings Per Share (EPS)
0.93
TTM Avg
-0.44
3Y Avg
-0.74
5Y Avg
-1.38
Market Cap
$638.20M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
Market Cap
$619.15M
Earnings Per Share (EPS)
-1.15
TTM Avg
-1.06
3Y Avg
-1.18
5Y Avg
-1.14
Market Cap
$611.57M
Earnings Per Share (EPS)
-0.83
TTM Avg
-1.21
3Y Avg
-1.36
5Y Avg
-1.94
Market Cap
$656.59M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
Market Cap
$657.89M
Earnings Per Share (EPS)
-0.30
TTM Avg
-0.54
3Y Avg
-0.54
5Y Avg
-0.54
Market Cap
$660.29M
Earnings Per Share (EPS)
-1.16
TTM Avg
-1.18
3Y Avg
-1.68
5Y Avg
-2.29
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $630.63M | -0.36 | -0.59 | -0.49 | -0.39 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -1.10 | -1.50 | -1.66 | -1.44 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 0.93 | -0.44 | -0.74 | -1.38 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -1.78 | -1.75 | -1.85 | -1.69 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | -1.15 | -1.06 | -1.18 | -1.14 |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -0.83 | -1.21 | -1.36 | -1.94 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -2.72 | -2.70 | -2.77 | -2.61 |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | -0.30 | -0.54 | -0.54 | -0.54 |
| Annexon, Inc. (ANNX)vs › | $660.29M | -1.16 | -1.18 | -1.68 | -2.29 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 0.77 | 0.08 | -1.29 | -0.21 |
Trailing EPS (TTM)
$-0.36
Forward EPS (Est.)
$-0.36
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.57 |
| 2024-12-31 | -0.61 |
| 2023-12-31 | -0.51 |
| 2022-12-31 | -0.26 |
| 2021-12-31 | -0.24 |
| 2020-12-31 | -0.15 |
| 2019-12-31 | -0.12 |
